National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional ) | RFA DA 20 016

Opportunity Information: Apply for RFA DA 20 016

The National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional) grant opportunity (RFA DA 20 016) is a cooperative agreement offered by the National Institutes of Health, focused on building and operating a single national Coordinating Center that can track, interpret, and rapidly communicate emerging and ongoing drug misuse trends across the United States. The core idea is to strengthen the nation s ability to detect changes in drug markets and drug related harms early, using a coordinated, multi source approach that combines community level intelligence with larger administrative and surveillance datasets. Rather than funding multiple centers, this announcement is aimed at selecting one hub organization responsible for pulling together diverse information streams, standardizing how data are handled across locations, and turning that information into timely analyses and practical products for public health and public safety stakeholders.

A major responsibility of the Coordinating Center is to maintain the governance and expert input needed to keep an early warning system scientifically credible and operationally useful. This includes maintaining a Scientific Advisory Group to provide ongoing guidance on methods, interpretation, and priorities, and maintaining and refining an Early Warning Network made up of local experts from selected communities along with NIDA supported community based researchers. These local partners are positioned to notice shifts that may not show up quickly in national datasets, such as sudden spikes in overdoses linked to a new synthetic opioid, changes in counterfeit pill supply, new stimulant combinations, or local patterns of polysubstance use. The network is expected to support continuous monitoring and help interpret signals in context so that the system does not just report numbers but explains what they likely mean on the ground.

Another central task is creating and maintaining a consistent set of key community level indicators that can be compared across places and over time. The FOA emphasizes indicator harmonization, meaning the Coordinating Center is expected to standardize definitions, formats, analytic approaches, and how results are displayed and reported across participating communities. This is important because drug trend data often come from systems that were designed for other purposes and vary widely by jurisdiction, so harmonizing them can make cross site analysis possible and reduce confusion among end users. These indicators are meant to support both routine monitoring of established drug trends and early identification of new synthetic drugs or emerging issues before they become widespread crises.

The Coordinating Center is also expected to continually identify, incorporate, and maintain novel or high value data sources that can improve detection and situational awareness. Examples specifically noted include treatment admissions data, national measures of drug use among adults and youth, law enforcement seizure data, and drug poisoning death data. In practice, this implies building repeatable pipelines and relationships that allow the center to access data in a timely way, assess quality, and integrate it with other sources. The goal is to capture a fuller picture of the drug landscape, from use patterns and treatment demand to supply side indicators and mortality outcomes.

Once indicators and sources are harmonized, the Coordinating Center must conduct cross site analyses using the combined data. That means looking for regional and national patterns, identifying clusters or spread of specific substances, comparing how trends differ across communities, and examining how signals in one data stream line up with signals in another. The expectation is that the center will not simply compile data, but actively analyze it to generate actionable findings that can inform prevention, clinical responses, harm reduction strategies, and policy decisions.

Dissemination is treated as a core deliverable, not an afterthought. The center is expected to execute publication and dissemination plans and to continually explore better ways to share results quickly and clearly with different audiences. A specific requirement is development and maintenance of a public facing website to disseminate data and findings. In addition, the center must conduct webinars on topics that matter to stakeholders, which can include emerging drug threats, interpretation of new signals, or best practices for responding to specific trends. The emphasis on multiple dissemination channels reflects the need to reach public health departments, clinicians, community organizations, researchers, and public safety agencies with information that is both timely and usable.

Beyond monitoring and reporting, the FOA also calls for on the ground epidemiologic investigations when there is an immediate crisis or urgent need. This suggests the Coordinating Center should have the capacity to quickly investigate sudden overdose spikes, unusual toxicology findings, or other acute events, and then provide practical feedback to affected communities. The intent is to shorten the loop between detection and response, so that communities receive functional, near term guidance that can improve current interventions and strengthen future readiness.

Because this is a Coordinating Center award, strong operations and management capacity are essential. The center must provide operational, administrative, and logistical support for the harmonization and dissemination initiative, which typically includes project management, coordination across sites and partners, data governance and documentation, meeting and webinar logistics, and ongoing communication with NIH and participating communities. As a cooperative agreement (U01), the funding mechanism also implies substantial NIH involvement in the project, with the awardee working collaboratively with the agency on priorities and implementation.

In terms of eligibility, the FOA is open to a broad set of domestic applicants, including state, county, and local governments, special district governments, independent school districts, public housing authorities, federally recognized tribal governments, and tribal organizations. It also allows public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for profit organizations (other than small businesses), and small businesses, as well as certain mission focused institution types such as HBCUs, Hispanic serving institutions, AANAPISI institutions, TCCUs, Alaska Native and Native Hawaiian serving institutions, and faith based or community based organizations. However, foreign institutions are not eligible to apply, foreign components of U.S. organizations are not allowed, and non U.S. components of U.S. organizations are not eligible, consistent with NIH policy restrictions stated in the announcement.

Key administrative details from the listing include an original closing date of 2019 08 14, an award ceiling of 550,000, and that it sits within the NIH CFDA program number 93.279. The activity focus is in education and health, with the overall purpose of strengthening national capacity to identify and respond to emerging drug threats through coordinated data collection, harmonization, analysis, rapid field investigation when needed, and wide dissemination of clear, decision ready findings.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional )" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2019-05-31.
• Applicants must submit their applications by 2019-08-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $550,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 20 016

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: